NCT06824467Phase 3Listed as recruiting
Recurrent platinum-sensitive ovarian cancer: a new maintenance treatment compared with standard care
The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.
Minimum age: 18 years
Centres in: București · Cluj-Napoca · Craiova · and one more city
See all centres (5)Hide the centre list
These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.
Central study contact
To find the team and exact institution in your chosen city, quote study NCT06824467. This contact may be in another country; ask which language you can use.
Source: study registry
We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.
București
Spitalul Clinic Filantropia
SC MNT Healthcare Europe SRL
Cluj-Napoca
Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca
Craiova
S.C. Centrul de Oncologie Sf. Nectarie SRL
Timișoara
Cabinet Medical Oncomed
Who can take part
Recurrent platinum-sensitive ovarian cancer: a new maintenance treatment compared with standard care
The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.
- Minimum age:
- 18 years
- Maximum age:
- Not specified in the record consulted
- Participant sex, as recorded in the registry:
- Female
This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.
Criteria published in the registry — English original
Inclusion Criteria: * Has locally advanced or metastatic, histologically confirmed epithelial ovarian, primary peritoneal, or fallopian tube carcinoma of certain histologies * Has received 4 or more cycles of platinum-based doublet chemotherapy in first-line and a total of 6 to 8 cycles of carboplatin-based doublet chemotherapy in second-line setting for ovarian cancer (OC) * Has platinum-sensitive epithelial OC * Has provided tissue of a tumor lesion that was not previously irradiated * Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy * Participants who are hepatitis B surface antigen positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to allocation (Part 1) or randomization (Part 2) * Participants with a history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening * Has an ECOG performance status of 0 or 1 assessed within 7 days before allocation (Part 1) or randomization (Part 2) Exclusion Criteria: * Has nonepithelial cancers (germ cell tumors and sex cord-stromal tumors), low-grade serous tumors, low-grade endometrioid tumors, borderline tumors (low malignant potential), mucinous, seromucinous that is predominantly mucinous, malignant Brenner's tumor and undifferentiated carcinoma * Has platinum-resistant OC or platinum-refractory OC * Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing * Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis, or chronic diarrhea) * Has uncontrolled, significant cardiovascular disease or cerebrovascular disease * Has a history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids, has current pneumonitis/ILD, or has suspected pneumonitis or ILD that cannot be ruled out by standard diagnostic assessments at Screening * HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease * Has received more than 2 prior lines of systemic therapy for OC * Has received prior systemic anticancer therapy within 3 weeks or 5 half-lives (whichever is shorter) before allocation (Part 1) or randomization (Part 2) * Has received prior radiotherapy within 2 weeks of allocation (Part 1) or randomization (Part 2), or has radiation related toxicities, requiring corticosteroids * Has an additional malignancy that is progressing or has required active treatment within the past 3 years * Has active central nervous system (CNS) metastases and/or carcinomatous meningitis * Has an active infection requiring systemic therapy * Has active or ongoing stomatitis
What taking part involves
Participants are randomly assigned to the study groups.
These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.
Group 1 · Studied intervention
Sacituzumab tirumotecan · Bevacizumab · H1 receptor antagonist · H2 receptor antagonist · Acetaminophen (or equivalent) · Dexamethasone (or equivalent) · Steroid mouthwash (dexamethasone or equivalent)
Group 2 · Studied intervention
Sacituzumab tirumotecan · Bevacizumab · H1 receptor antagonist · H2 receptor antagonist · Acetaminophen (or equivalent) · Dexamethasone (or equivalent) · Steroid mouthwash (dexamethasone or equivalent)
Group 3 · Active treatment comparison
Bevacizumab
- Start of the whole study
- 9 April 2025
- Completion of the whole study
- 9 November 2032 (estimated)
These are global study dates, not an individual's participation duration or an enrolment deadline.
Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.
Ask the study team before travelling:
- whether places are available at the chosen centre and how the first assessment is arranged
- how often you need to attend the centre and whether a hospital stay is necessary
- whether travel or accommodation costs are covered and under what conditions
- which documents you need to prepare and whether a family member or carer can accompany you
Original registry title
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Updated in the registry: 17 November 2026
Data consulted: 19 November 2026
See the official record ↗If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.
